OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

Development Collaboration Will Initially Focus on CAR T-Cell Therapy for Triple-Negative Breast Cancer SAN DIEGO and PENNINGTON, N.J., June 27, 2019 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a co... Biopharmaceuticals, Oncology, Licensing OncoSec Medical, CAR T-cell, CAR T-cell therapies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news